Previous 10 | Next 10 |
REHOVOT, Israel and BRIDGEWATER, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, announc...
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Of...
Foamix Pharmaceuticals (NASDAQ: FOMX ): Q1 GAAP EPS of -$0.28 beats by $0.01 . Revenue of $0.31M (-65.9% Y/Y) misses by $0.71M . Cash and equivalents of $82.9M. Press Release More news on: Foamix Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, ,
FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for Wednesday May 8 th at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix ...
REHOVOT, Israel, and BRIDGEWATER, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in de...
REHOVOT, Israel and BRIDGEWATER, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical thera...
REHOVOT, Israel and BRIDGEWATER, N.J., April 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in der...
It looks as if 2019 is set up to be a transformational year for Foamix Pharmaceuticals ( FOMX ) with a potential conversion from a developmental stage to commercial-stage biotech. The company reached a key milestone in December with the filing of their first NDA for the company’s FMX1...
REHOVOT, Israel and BRIDGEWATER, N.J., April 02, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical thera...
REHOVOT, Israel and BRIDGEWATER, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in...
News, Short Squeeze, Breakout and More Instantly...
Foamix Pharmaceuticals Ltd. Company Name:
FOMX Stock Symbol:
NASDAQ Market:
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and...